Site Editor

Sandy Srinivas, MD

Advertisement

Advertisement

News

Nonmetastatic Castration-Resistant Prostate Cancer: Benefits/Risks of Second-Generation AR Inhibitors in Older Men

News

Bone Resorption Inhibitors: Are They of Benefit to Patients Being Treated for Metastatic Prostate Cancer?

News

Does Early Initiation of ADT Improve Outcomes in Biochemically Recurrent Prostate Cancer?

Medical Literature

Multimodal Treatment and Mortality Outcomes in High-Risk Prostate Cancer

News

FDA Guidance for Using Metastasis-Free Survival as a Prostate Cancer Trial Endpoint

Medical Literature

Mortality Risk and PSA Failure in Localized Versus Locally Advanced Prostate Cancer

Medical Literature

Prognostic Factors for Decisional Regret Regarding Treatment in Localized Prostate Cancer

Michael J. Morris, MD: Can Lutetium-177–PSMA-617 Plus Standard of Care Improve Outcomes in Advanced Prostate Cancer?

Nicholas D. James, PhD, MBBS, on Clinical Implications of STAMPEDE Trial Results: Abiraterone Acetate Plus Prednisolone in Prostate Cancer

View More

Advertisement

JNCCN Spotlights

Docetaxel (Castration-Naive Metastatic Prostate Cancer)

(UPDATE) Enzalutamide (Xtandi®)

Degarelix (Injectable GnRH Antagonist)

(UPDATE) Apalutamide in Prostate Cancer

View More

More

News

FDA Brief: Radioligand Therapy Receives Breakthrough Therapy Designation in Prostate Cancer

Treating Low- to Intermediate-Risk Prostate Cancer With Targeted Focal Microwave Ablation

Risk of Cardiovascular Events Following Hormone Therapy for Prostate Cancer

Transcriptional Profiles From Liquid Biopsy: A Prognostic Marker in Metastatic Prostate Cancer?

ASCO 2021: Early-Phase Study of Alpha Emitter in Castration-Resistant Prostate Cancer

Do Common Prostate Cancer Treatments Cause Cognitive Decline?

Radiation Escalation and Short-Term Androgen Suppression in Prostate Cancer

Dual Pathway Inhibition Under Study in Metastatic Castration-Resistant Prostate Cancer

View More

Advertisement

Published

Medical Literature

Preradiation Testosterone Levels and Aggressiveness of Prostate Cancer

Can Prostate Cancer Surveillance Be Tailored to Individual Risk?

Prostate Cancer and Type 2 Diabetes: Focus on Outcomes and Metformin

Update on Trends in Initial Management of High-Risk Prostate Cancer

View More

Ongoing

CE Activities

Nursing Management of Treatment-Related Side Effects in Metastatic Prostate Cancer

MRI With Targeted Biopsy Matches Current Standard for ID'ing Prostate Cancer

Active Surveillance for Low-Risk Prostate Cancer Affected by Where Men Live

Differentiating GnRH Antagonists From GnRH Agonists: What Are the Latest Data in Prostate Cancer Showing?

View More

Available

Clinical Trials

University of Nebraska

Seidman Cancer Center

City of Hope

Dana-Farber Cancer Institute

View More

Resources

For Your Patients

NCCN Guidelines for Patients®: Prostate Cancer

National Alliance of State Prostate Cancer Coalitions (NASPCC)

Prostate Conditions Education Council (PCEC)

Cancer.Net

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2021 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.